Intuitive Surgical Inc
ISRG
Market Cap$139.04B
Close$
Earnings Call Q4 2023
January 23, 2024 - AI Summary
Intuitive reported strong performance in Q4 2023, with procedure growth of 21% and revenue growth of 17% year-over-year.
The company submitted a 510(k) application for its next-generation multiport platform, da Vinci 5, to the FDA. The launch timing will depend on the resolution of FDA's questions.
Full-year procedure growth for 2023 was 22%, driven by strength in general surgery procedures in the US and diversification beyond urology in international markets.
Exclusive for Stockcircle Pro members
Sign up
$99.56
73.4% downside
Current Fair Value
73.4% downsideOvervalued by 73.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $139.04 Billion |
|---|---|
| Enterprise Value | $133.81 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $5.03 |
| Beta | 1.25 |
| Outstanding Shares | 354,448,735 |
| Avg 30 Day Volume | 1,506,880 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 77.33 |
|---|---|
| PEG | 89.31 |
| Price to Sales | 18.71 |
| Price to Book Ratio | 10.11 |
| Enterprise Value to Revenue | 18.78 |
| Enterprise Value to EBIT | 75.74 |
| Enterprise Value to Net Income | 74 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
ESG Score
No data
About Intuitive Surgical Inc
CEO: Gary Guthart